Cachexia is diagnosed primarily by tracking unintentional weight loss, typically more than 5% of body weight within six months, in the presence of an underlying chronic illness. There is no single test that confirms it. Instead, doctors use a combination of weight history, body composition measurements, blood markers, and functional assessments to make the diagnosis and determine its severity.
The Core Diagnostic Criteria
The most widely used framework, established by international consensus in 2011, diagnoses cachexia when a patient meets one of these thresholds over the preceding six months: weight loss greater than 5%, or weight loss greater than 2% in someone who already has a low body mass index (below 20) or low muscle mass. The weight loss must be unintentional and not explained by simple starvation, meaning there needs to be an underlying disease driving the wasting.
An earlier set of criteria from 2008 used a 12-month window and required at least three additional clinical features alongside the 5% weight loss: fatigue, loss of appetite, abnormal blood work, low lean body mass, or decreased muscle strength. Cancer patients typically show faster decline, so the timeframe was shortened to three to six months in later definitions. Both frameworks remain in clinical use, which is one reason cachexia can sometimes be inconsistently identified across different care settings.
Stages of Cachexia
Cachexia progresses through three recognized stages, each with its own diagnostic thresholds:
- Pre-cachexia: Weight loss of more than 1 kilogram but less than 5% of body weight. Patients at this stage often have early signs of appetite loss and metabolic changes but haven’t yet crossed into significant wasting.
- Cachexia: Weight loss greater than 5%, or greater than 2% with a BMI under 20 or confirmed low muscle mass.
- Refractory cachexia: Weight loss exceeding 15% with a BMI below 23, or weight loss exceeding 20% with a BMI below 27. At this stage, the wasting process is largely irreversible and no longer responds to treatment of the underlying disease.
Catching cachexia at the pre-cachexia stage appears to offer the best chance of slowing its progression, which is why routine weight monitoring matters for anyone living with a chronic illness like cancer, heart failure, or COPD.
Blood Tests Used in Diagnosis
No single blood test confirms cachexia, but two markers help support the diagnosis. C-reactive protein (CRP), a measure of systemic inflammation, is often elevated above 5 to 10 mg/L in cachectic patients. Serum albumin, a protein made by the liver that reflects nutritional status, is typically low, falling below 32 to 35 g/L. When CRP rises above 10 mg/L and albumin drops below 30 g/L at the same time, this combination has been described as “laboratory cachexia.”
In patients with advanced cancer approaching death, these values can become dramatically abnormal. One study found median CRP levels of 84 mg/L and albumin levels of just 23 g/L in the final 30 days of life. These blood markers serve as supporting evidence rather than standalone diagnostic tools, and they also help distinguish cachexia from conditions like age-related muscle loss, where systemic inflammation is typically absent.
Measuring Muscle Loss
Because cachexia specifically destroys skeletal muscle, measuring muscle mass is a key part of the diagnostic workup. CT scans are the most precise method, particularly in cancer patients who are already getting regular imaging. Doctors measure the skeletal muscle index at specific vertebral levels. For men, a value below 55 cm²/m² (measured at the third lumbar vertebra) indicates low muscle mass. For women, the threshold is below 39 cm²/m².
When CT imaging isn’t available or practical, a simple screening questionnaire called SARC-F can flag people at risk for significant muscle loss. It scores five items related to strength, walking ability, rising from a chair, stair climbing, and falls. A score of 4 or higher suggests the person should be evaluated further for muscle wasting. It’s not a cachexia-specific tool, but it provides a fast, no-cost way to identify who needs a closer look.
Grip Strength and Physical Function
Handgrip strength is one of the simplest and most informative tests in cachexia assessment. It’s measured with a handheld device called a dynamometer, which you squeeze as hard as you can. Current thresholds define low grip strength as below 27 kg for men and below 16 kg for women. These cutoffs correlate strongly with mortality risk and functional decline.
Context matters, though. A 60-year-old man of average height who grips below about 46 kg already shows elevated mortality risk compared to his peers, while for a 70-year-old man, that threshold drops to around 41 kg. This age-dependent variation means grip strength results need to be interpreted relative to the patient’s demographics rather than against a single universal number. In practice, declining grip strength over time is often more telling than any single measurement.
How Cachexia Differs From Sarcopenia and Starvation
One of the most important parts of diagnosis is distinguishing cachexia from two conditions that can look similar on the surface: age-related muscle loss (sarcopenia) and simple starvation.
Sarcopenia is a gradual, age-driven process. It involves muscle loss and weakness, but fat mass often increases, resting energy expenditure drops, and inflammation is minimal or absent. Cachexia, by contrast, burns through both muscle and fat, ramps up the body’s resting energy expenditure, and is fueled by significant inflammation from an underlying disease. Protein breakdown in cachexia is aggressive in a way that sarcopenia’s slow decline is not.
Starvation differs because it’s driven by inadequate food intake without a disease stoking the metabolic fire. A starving person who regains access to nutrition can rebuild lost tissue. Cachexia resists conventional nutritional support. You can increase caloric intake and still lose weight, because the underlying illness reprograms the body’s metabolism to break down its own tissues. This resistance to feeding is, in many ways, the hallmark that separates cachexia from other forms of weight loss and makes early identification so critical.